Post-essential Thrombocythemia Myelofibrosis clinical trials at University of California Health

2 in progress, 0 open to eligible people

Showing trials for

  • Pelabresib (CPI-0610) in Myelofibrosis (MF) (MANIFEST-2)

    Sorry, in progress, not accepting new patients

    A Phase 3, randomized, blinded study comparing pelabresib (CPI-0610) and ruxolitinib with placebo and ruxolitinib in myelofibrosis (MF) patients that have not been previously treated with Janus kinase inhibitors (JAKi). Pelabresib is a small molecule inhibitor of bromodomain and extra-terminal (BET) proteins.

    at UCLA UCSD

  • Parsaclisib and Ruxolitinib in Participants With Myelofibrosis (LIMBER-313)

    Sorry, in progress, not accepting new patients

    The purpose of the study is to compare the efficacy of parsaclisib when combined with ruxolitinb versus placebo combined with ruxolitinib in participants with myelofibrosis.

    at UCLA

Our lead scientists for Post-essential Thrombocythemia Myelofibrosis research studies include .

Last updated: